Ozmosi | Duodopa Drug Profile

Product Description

Mechanisms of Action: DDC Inhibitor, DR Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Indications: None

Known Adverse Events: None

Company: AbbVie
Company Location: Eastern America
Company Founding Year: 2013
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Duodopa

Countries in Clinic: Austria, Belgium, Czech Republic, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, Portugal, Russia, Slovakia, Spain, Ukraine, United Kingdom, United States

Active Clinical Trial Count: 6

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Parkinson's Disease

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
2024-511940-20-00	ND0612-317	P3	Active, not recruiting	Parkinson's Disease	2027-05-06		2025-05-02	Treatments
2024-513548-27-00	ND0612H-012	P2	Active, not recruiting	Parkinson's Disease	2027-05-23		2025-05-02	Treatments
NCT02726386	BeyoND	P2	Active, not recruiting	Parkinson's Disease	2019-09-09	12%	2024-01-20	Primary Completion Date\|Primary Endpoints\|Start Date\|Treatments
2018-004156-37	BouNDless	P3	Active, not recruiting	Parkinson's Disease	2023-05-18		2025-05-06	Treatments
NCT04006210	BouNDless	P3	Active, not recruiting	Parkinson's Disease	2022-11-01	66%	2023-11-08	Primary Endpoints
2016-002033-30	iNDiGO	P3	Active, not recruiting	Parkinson's Disease	2017-04-27		2022-03-13	Treatments

Recent News Events

Date	Type	Title
05/01/2024	PubMed	Effect of levodopa on pathological gait in Dravet syndrome: A randomized crossover trial using three-dimensional gait analysis.
05/01/2024	PubMed	Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial.
02/08/2024	News Article	AbbVie's VYALEV™ (foslevodopa/foscarbidopa solution) Available for the Treatment of Advanced Parkinson's Disease in Canada
09/07/2022	News Article	Dizlin Pharmaceuticals publishes data from pharmacokinetic study (PK) (IPO-001) with Infudopa SubC (DIZ102) and Infudopa IntraV (DIZ101) in Neurology
09/10/2021	News Article	AbbVie to Highlight Its Leadership in Movement Disorders at the International Parkinson and Movement Disorder Society Virtual Congress 2021
09/11/2020	News Article	AbbVie to Present New Data From 18 Abstracts at the International Congress of Parkinson's Disease and Movement Disorders®

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Duodopa

Alternative Names: duodopa, dm-1992, dm1992, dm 1992, ipx-066, ipx066, ipx 066, nd-0612, nd0612, nd 0612 Clinical Status: Active Latest Update: 2025-01-29 Latest Update Note: Clinical Trial Update